Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger M Lyons

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Leukemia Research|December 10, 2013
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registryRoger M Lyons, Billie J Marek, Carole Paley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple MyelomaXavier Leleu, Thomas G Martin, Hermann Einsele, et al.
Leukemia Research|March 1, 2017
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 yearsRoger M Lyons, Billie J Marek, Carole Paley, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
JAMA Internal Medicine|April 16, 2014
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirinBruce L Davidson, Sara Verheijen, Anthonie W A Lensing, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
Leukemia & Lymphoma|January 15, 2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximabRoger M Lyons, Mikhail Shtivelband, Edwin Kingsley, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
American Journal of Hematology|October 31, 2003
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine careJames N George, Gary E Raskob, Sara K Vesely, et al.
Investigational New Drugs|September 17, 2011
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemiaCraig Reynolds, Nicholas Di Bella, Roger M Lyons, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Leukemia Research|December 10, 2013
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registryRoger M Lyons, Billie J Marek, Carole Paley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple MyelomaXavier Leleu, Thomas G Martin, Hermann Einsele, et al.
Leukemia Research|March 1, 2017
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 yearsRoger M Lyons, Billie J Marek, Carole Paley, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
JAMA Internal Medicine|April 16, 2014
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirinBruce L Davidson, Sara Verheijen, Anthonie W A Lensing, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
Leukemia & Lymphoma|January 15, 2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximabRoger M Lyons, Mikhail Shtivelband, Edwin Kingsley, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
American Journal of Hematology|October 31, 2003
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine careJames N George, Gary E Raskob, Sara K Vesely, et al.
Investigational New Drugs|September 17, 2011
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemiaCraig Reynolds, Nicholas Di Bella, Roger M Lyons, et al.
Pageof 5